Eli Lilly reported positive top‑line results from Transcend‑T2D‑1: the triple‑agonist retatrutide produced clinically meaningful A1C reductions and substantial weight loss in people with type 2 diabetes. The phase III readout showed A1C decreases up to ~1.9–2.0 percentage points and weight losses averaging as much as 36.6 pounds at the highest dose over 40 weeks, with safety consistent with the GLP family. Retatrutide targets GLP‑1, GIP and glucagon receptors, positioning it as a potential next‑generation metabolic drug. Lilly emphasized the drug met all key secondary endpoints and highlighted continued monitoring of adverse events such as gastrointestinal effects and rare sensory complaints; independent experts called the efficacy notable but cautioned that peer‑reviewed data and long‑term safety readouts are still needed.